Video - Results from #50

ASCO GU 2022 VL

Search

DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky Details Alicia Morgans and Matthew Galsky discuss a two-part open-label study of trastuzumab deruxtecan with nivolumab in patients with HER2 expressing urothelial carcinoma. Dr. Galsky provides background on the rise of combination therapies of antibody-drug conjugates and immune checkpoint blockades in urothelial cancer. They also discuss the preliminary success of this combination therapy and that we wi...
Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski Details Daniel Spratt and Jeff Michalski discuss the pivotal NRG Oncology RTOG 0126 trial from which Dr Michalski is the PI. This phase III randomized NRG/RTOG 0126 trial provides the first validation of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer. Dr. Spratt provides the background on the rationale for the NRG/RTOG 0126 and the results from the RTOG 0126 trial. They discus...
First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi Details Alicia Morgans speaks with Kim Chi about the MAGNITUDE trial presented at GU ASCO 2022. The Phase III trial investigates the efficacy of combining niraparib, a PARP inhibitor, with abiraterone and prednisone in treating metastatic castration-resistant prostate cancer (mCRPC). The study focuses on patients with and without homologous recombination repair (HRR) gene alterations. Results reveal that...
Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde Details Ashish Kamat hosts Guru Sonpavde to discuss key findings from the GU ASCO symposium. Dr. Sonpavde reviews a range of groundbreaking studies, emphasizing the potential of systemic therapy for metastatic bladder cancer. Noteworthy trials include TROPHY-U-01, which shows a 34% response rate combining sacituzumab govitecan with pembrolizumab, and a study on neoadjuvant enfortumab vedotin revealing a 3...
Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas Details Alicia Morgans talks with Petros Grivas about the TROPHY-U-01 study, which evaluates the efficacy of combining Sacituzumab govitecan (SG) with anti-PD-1 pembrolizumab in patients with platinum-refractory advanced urothelial cancer. Dr. Grivas elaborates on the study's rationale, citing SG's FDA approval based on a 27% response rate and tolerability. The study aims to explore the potential benefits...
Next-Generation Sequencing: Discussing Results with Patients - Bishoy Faltas Details Alicia Morgans and Bishoy Faltas delve into the complexities and nuances of Next-Generation Sequencing (NGS) in clinical practice. Dr. Faltas emphasizes the importance of understanding the technical aspects of NGS, such as the type of sequencing and the coverage, to interpret results accurately. He also highlights the need for clinicians to be aware of the computational analysis that NGS undergoes...
Anticipated Data from Transformative Trials at ASCO GU 2022 - Oliver Sartor Details Alicia Morgans and Oliver Sartor discuss the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on Feb 17-20, 2022, and the data from key presentations in prostate cancer, bladder cancer, and kidney cancer. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Resear...